EyePoint Pharmaceuticals Investor Day to Highlight EYP-1901 and Durasert® Technology Developments and Provide a Financial UpdateGlobeNewsWire • 07/18/22
EyePoint Pharmaceuticals (EYPT) Soars 21.6%: Is Further Upside Left in the Stock?Zacks Investment Research • 07/18/22
EyePoint Pharmaceuticals Announces Positive 12-Month Safety and Efficacy Data from Phase 1 DAVIO Clinical Trial Evaluating EYP-1901 for the Treatment of Wet AMDPRNewsWire • 07/15/22
EyePoint Pharmaceuticals (EYPT) Loses 25.2% in 4 Weeks, Here's Why a Trend Reversal May be Around the CornerZacks Investment Research • 06/27/22
EyePoint Pharmaceuticals Announces Election of Tony Adamis, M.D. to Board of DirectorsGlobeNewsWire • 06/23/22
EyePoint Pharmaceuticals and OcuMension Therapeutics Announce Approval of New Drug Application by China's NMPA for YUTIQ® for the Treatment of Chronic Non-Infectious Uveitis Affecting the Posterior Segment of the EyeGlobeNewsWire • 06/21/22
EyePoint Pharmaceuticals to Present 12-Month Results from Phase 1 DAVIO Clinical Trial Evaluating EYP-1901 for the Treatment of Wet AMD at the American Society of Retina Specialists 2022 Annual MeetingGlobeNewsWire • 06/10/22
EyePoint Pharmaceuticals to Present at the H.C Wainwright Global Healthcare Investment ConferenceGlobeNewsWire • 05/17/22
Down 18.2% in 4 Weeks, Here's Why You Should You Buy the Dip in EyePoint Pharmaceuticals (EYPT)Zacks Investment Research • 05/10/22
EyePoint Pharmaceuticals, Inc. (EYPT) CEO Nancy Lurker on Q1 2022 Earnings Call TranscriptSeeking Alpha • 05/04/22
EyePoint, Expands Pact With Betta Pharma For EYP-1901 In China, Posts Deeper Q1 LossBenzinga • 05/04/22
EyePoint Pharmaceuticals (EYPT) Reports Q1 Loss, Lags Revenue EstimatesZacks Investment Research • 05/04/22
EyePoint Pharmaceuticals Reports First Quarter 2022 Financial Results and Highlights Recent Corporate DevelopmentsGlobeNewsWire • 05/04/22
EyePoint Pharmaceuticals Announces Expanded License Agreement with Betta Pharmaceuticals for EYP-1901 in China, Hong Kong, Macau and TaiwanGlobeNewsWire • 05/04/22
EyePoint Pharmaceuticals to Report First Quarter 2022 Financial Results on May 4, 2022GlobeNewsWire • 04/27/22
EyePoint Pharmaceuticals to Participate in Fireside Chat at the B. Riley 2022 Virtual Neuro & Ophthalmology ConferenceGlobeNewsWire • 04/21/22
EyePoint Pharmaceuticals Announces Debt Refinancing with $45M Credit Facilities from Silicon Valley BankGlobeNewsWire • 03/09/22
EyePoint Pharmaceuticals Appoints Isabelle Lefebvre as Chief Regulatory OfficerGlobeNewsWire • 03/07/22
EyePoint Pharmaceuticals, Inc. (EYPT) CEO Nancy Lurker on Q4 2021 Results - Earnings Call TranscriptSeeking Alpha • 03/03/22
EyePoint Pharmaceuticals Reports Fourth Quarter and Full-Year 2021 Financial Results and Highlights Recent Corporate DevelopmentsGlobeNewsWire • 03/03/22
EyePoint Pharmaceuticals to Participate in Fireside Chat at the Cowen 42nd Annual Health Care ConferenceGlobeNewsWire • 03/01/22
EyePoint Pharmaceuticals to Report Fourth Quarter and Full-Year 2021 Financial Results on March 3, 2022GlobeNewsWire • 02/24/22